Engineered exosomes that display tumor-specific targeting moieties (such as anti-HER2 antibodies) or pH-sensitive release properties can accumulate preferentially in tumor tissues, significantly improving the therapeutic efficacy over conventional chemotherapeutic agents while reducing off-target toxicity substantially. The gene discussed is ERBB2; the disease is neoplasm.